Illumina (NASDAQ:ILMN) Director Keith Meister Sells 131,019 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN – Get Free Report) Director Keith Meister sold 131,019 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $225.51, for a total transaction of $29,546,094.69. Following the transaction, the director directly owned 1,278,832 shares in the company, valued at approximately $288,389,404.32. The trade was a 9.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Illumina Price Performance

Shares of NASDAQ ILMN traded up $2.85 during trading on Thursday, hitting $227.69. The company had a trading volume of 1,937,136 shares, compared to its average volume of 2,109,322. The firm has a market capitalization of $34.38 billion, a price-to-earnings ratio of 42.48, a price-to-earnings-growth ratio of 3.16 and a beta of 1.45. The stock has a fifty day simple moving average of $192.98 and a two-hundred day simple moving average of $155.18. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $231.81.

Get Illumina alerts:

Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current year.

Institutional Investors Weigh In On Illumina

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Empowered Funds LLC increased its stake in Illumina by 113.7% in the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after purchasing an additional 4,940 shares during the period. Sivia Capital Partners LLC acquired a new position in Illumina in the 2nd quarter valued at about $621,000. CW Advisors LLC acquired a new stake in Illumina during the 2nd quarter worth approximately $275,000. Marshall Wace LLP increased its holdings in shares of Illumina by 49.0% in the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after purchasing an additional 19,618 shares during the period. Finally, Cresset Asset Management LLC raised its stake in shares of Illumina by 30.9% during the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after purchasing an additional 1,748 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on ILMN. Barclays increased their target price on Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a report on Friday, July 31st. Sanford C. Bernstein reissued a “market perform” rating and issued a $215.00 price objective on shares of Illumina in a research note on Friday, July 31st. Leerink Partners lifted their target price on shares of Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a research note on Friday, July 17th. JPMorgan Chase & Co. increased their target price on shares of Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Finally, Canaccord Genuity Group boosted their price target on shares of Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Illumina has a consensus rating of “Hold” and a consensus target price of $188.40.

Check Out Our Latest Stock Report on ILMN

Illumina Company Profile

(Get Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Read More

• Five stocks we like better than Illumina
• Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
• SEC Probe Puts Wall Street Leverage Risk Back in Focus
• A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
• Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.